title: The role of CCL22 (MDC) for the recruitment of eosinophils during allergic pleurisy in mice.
abstract: Eosinophils are important inflammatory cells in allergic diseases. In the present study, we have investigated the effects of CCL22 on the recruitment of eosinophils in vivo and in vitro. CCL22 induced a dose- and time-dependent recruitment of eosinophils into the pleural cavity of mice, and this was dependent on the release of platelet-activating factor (PAF) and subsequent generation of CCL11. However, in an allergic pleurisy model, an anti-CCL22 polyclonal antibody given during sensitization or before challenge had no significant effect on eosinophil recruitment. CCL22 did not induce eosinophil chemotaxis in vitro but was able to induce eosinophil degranulation in vitro and in vivo. In conclusion, we show that although exogenously added CCL22 may induce eosinophil migration in vivo via release of PAF and CCL11 (eotaxin), endogenous production of CCL22 does not drive eosinophil migration during allergic inflammation. However, CCL22 may be an important activator of eosinophils once these cells have migrated into tissue.
authors.affiliation: Immunopharmacology, Departamento de Bioquímica e Imunologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Pinho
authors.forename: Sandra H
authors.initials: SH
authors.lastname: Oliveira
authors.forename: Danielle G
authors.initials: DG
authors.lastname: Souza
authors.forename: Denise
authors.initials: D
authors.lastname: Vasconcelos
authors.forename: Ana Letícia
authors.initials: AL
authors.lastname: Alessandri
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Lukacs
authors.forename: Mauro M
authors.initials: MM
authors.lastname: Teixeira
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D015550:Cell Degranulation / Q000187:drug effects; D054413:Chemokine CCL11; D054422:Chemokine CCL22; D019742:Chemokines, CC / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology* / Q000502:physiology; D002631:Chemotactic Factors, Eosinophil / Q000276:immunology / Q000502:physiology; D002633:Chemotaxis / Q000187:drug effects*; D004804:Eosinophils / Q000166:cytology*; D006967:Hypersensitivity / Q000473:pathology; D007975:Leukotriene B4 / Q000502:physiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D010980:Platelet Membrane Glycoproteins / Q000235:genetics / Q000502:physiology; D010998:Pleurisy / Q000276:immunology / Q000473:pathology*; D011956:Receptors, Cell Surface / Q000235:genetics / Q000502:physiology; D043562:Receptors, G-Protein-Coupled
chemical_list: D000906:Antibodies; C515457:Ccl11 protein, mouse; C515483:Ccl22 protein, mouse; D054413:Chemokine CCL11; D054422:Chemokine CCL22; D019742:Chemokines, CC; D002631:Chemotactic Factors, Eosinophil; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D007975:Leukotriene B4